Want to see XFOR full AI Analyst Report?
X4 Pharmaceuticals (XFOR) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mavorixafor | Hepatic Insufficiency | Phase I | Recruiting | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Feb 27, 2025 | ― |
| Carbamazepine, Efavirenz, Mavorixafor | Healthy Participants | Phase I | Completed | Drug-Drug Interaction Potential of Mavorixafor | Feb 27, 2025 | ― |
| Mavorixafor | Neutropenia | Phase III | Recruiting | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Sep 20, 2023 | ― |
| Ibrutinib, Mavorixafor | Waldenstrom's Macroglobulinemia | Phase I | Completed | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | Feb 12, 2020 | ― |
| Mavorixafor | Neutropenia | phase1AndPhase2 | Completed | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | Nov 04, 2019 | ― |
| Mavorixafor | Whim Syndrome | Phase III | Active Not Recruiting | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Jun 19, 2019 | ― |
| X4p-001 | Whim Syndrome | Phase II | Completed | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Dec 20, 2016 | ― |
| Nivolumab, X4p-001 | Clear Cell Renal Cell Carcinoma | phase1AndPhase2 | Terminated | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Sep 30, 2016 | ― |
| Pembrolizumab, X4p-001 | Melanoma | Phase I | Completed | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | Jul 01, 2016 | ― |
| X4p-001 | Healthy | Phase I | Terminated | A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers | Feb 04, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mavorixafor | Phase I | Hepatic Insufficiency | Recruiting | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Feb 27, 2025 | ― |
| Carbamazepine, Efavirenz, Mavorixafor | Phase I | Healthy Participants | Completed | Drug-Drug Interaction Potential of Mavorixafor | Feb 27, 2025 | ― |
| Mavorixafor | Phase III | Neutropenia | Recruiting | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Sep 20, 2023 | ― |
| Ibrutinib, Mavorixafor | Phase I | Waldenstrom's Macroglobulinemia | Completed | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | Feb 12, 2020 | ― |
| Mavorixafor | phase1AndPhase2 | Neutropenia | Completed | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | Nov 04, 2019 | ― |
| Mavorixafor | Phase III | Whim Syndrome | Active Not Recruiting | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Jun 19, 2019 | ― |
| X4p-001 | Phase II | Whim Syndrome | Completed | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Dec 20, 2016 | ― |
| Nivolumab, X4p-001 | phase1AndPhase2 | Clear Cell Renal Cell Carcinoma | Terminated | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Sep 30, 2016 | ― |
| Pembrolizumab, X4p-001 | Phase I | Melanoma | Completed | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | Jul 01, 2016 | ― |
| X4p-001 | Phase I | Healthy | Terminated | A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers | Feb 04, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does X4 Pharmaceuticals (XFOR) have in its pipeline
X4 Pharmaceuticals XFOR is currently developing the following drugs: Mavorixafor, Carbamazepine, Efavirenz, Mavorixafor, Ibrutinib, Mavorixafor, X4p-001, Nivolumab, X4p-001, Pembrolizumab, X4p-001, X4p-001, Axitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.